<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02011035</url>
  </required_header>
  <id_info>
    <org_study_id>B2013:133</org_study_id>
    <nct_id>NCT02011035</nct_id>
  </id_info>
  <brief_title>Evaluating the Clinical Efficacy and Safety of Colflex</brief_title>
  <official_title>Evaluating the Clinical Efficacy and Safety of Colfelx</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Manitoba</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to test the safety and efficacy of Colflex, an oral spray created by
      Innotech Nutrition, on human subjects to measure changes on frequency/duration of colds and
      sore throats, as well as dental and oral health changes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and duration of colds/sore throats</measure>
    <time_frame>30 days</time_frame>
    <description>Using a self-reported scale to assess the frequency and during of colds and sore throats at screening, and at baseline and endpoint of treatments</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of oral pathogenic bacteria</measure>
    <time_frame>30 days</time_frame>
    <description>A mouth swab will be taken to measure pathogenic bacteria (Straph, Strep), and a mouth swab will be used for the BANA test to test for periodontal disease causing bacteria.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Effect on plasma lipid profile and enzyme measurements</measure>
    <time_frame>30 days</time_frame>
    <description>Exploratory efficacy measures include lipid profile, (TC, HDL, TG), and liver enzymes</description>
  </other_outcome>
  <other_outcome>
    <measure>Measurement of oral halitosis</measure>
    <time_frame>30 days</time_frame>
    <description>A breath sample is taken to measure volatile sulphur compounds using a halimeter.</description>
  </other_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Personal Satisfaction</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Residents in town
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  availability to give written consent

          -  age 18-60, men and women (who are not pregnant or nursing)

          -  people in good health

          -  able to follow protocol

          -  must be experiencing a sore throat or cold at least once a year

        Exclusion Criteria:

          -  smokers

          -  liver and kidney disease

          -  inflammatory bowel disease

          -  pancreatitis

          -  gallbladder or biliary disease

          -  neurolgical/psychological disease

          -  bleeding disorders

          -  platelet abnormatilies

          -  gastrointestinal disorders that could interfere with fat absorption

          -  serum triglycerides &gt; 500 mg/dL and/or total cholesterol &gt; 300 mg/dL

          -  hypertension (systolic blood pressure &gt;160 mm Hg or diastolic blood pressure &gt; 100 Hg

          -  BMI &gt;30

          -  consume or planned to consume anticoagulant, hypertension, or lipid lowering
             medications

          -  reported consumption of more than 2 alcoholic drinks/day or history of alcoholism or
             drug dependence

          -  reported use of experimental medication within 1 month prior to the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>RCFFN: University of Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3T2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2013</study_first_submitted>
  <study_first_submitted_qc>December 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2013</study_first_posted>
  <last_update_submitted>March 25, 2015</last_update_submitted>
  <last_update_submitted_qc>March 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Manitoba</investigator_affiliation>
    <investigator_full_name>Dr. Peter Jones</investigator_full_name>
    <investigator_title>Director of the Richardson Centre for Functional Foods and Nutraceuticals</investigator_title>
  </responsible_party>
  <keyword>Oral health</keyword>
  <keyword>Mouth health</keyword>
  <keyword>Halitosis</keyword>
  <keyword>Oral bacteria</keyword>
  <keyword>Sore throat</keyword>
  <keyword>Colds</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

